Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Liver X Receptors differentially modulate central myelin gene mRNA levels in a region-, age- and isoform-specific manner.
Deep-brain stimulation for Parkinson's disease.
Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.
Insight towards the conserved water mediated recognition of catalytic and structural Zn(+2) ions in human Matrix Metalloproteinase-8 enzyme: A study by MD-simulation methods.
Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial.
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
Fluoxetin Upregulates Connexin 43 Expression in Astrocyte.
Comparing individual and group intervention for psychological adjustment in people with multiple sclerosis: A feasibility randomised controlled trial.
Automatic multiple sclerosis lesion detection in brain MRI by FLAIR thresholding.
4-Аminopyridine sequesters intracellular Ca(2+) which triggers exocytosis in excitable and non-excitable cells.
A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases.
An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial.
Mast cells and inflammation.
Clinically isolated syndromes suggestive of multiple sclerosis: an optical coherence tomography study.
Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
CXCR7 suppression modulates microglial chemotaxis to ameliorate experimentally-induced autoimmune encephalomyelitis.
Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccine.
Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial.
Cognitive impairment among different clinical courses of multiple sclerosis.
Measurement and treatment of imbalance and fall risk in multiple sclerosis using the international classification of functioning, disability and health model.
An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Riboflavin Supplementation to Patients with Multiple Sclerosis does not Improve Disability Status nor is Riboflavin Supplementation Correlated to Homocysteine.
Erythromelalgia-like presentation of chronic acquired demyelinating polyneuropathy in a setting of past alcohol abuse.
Opexa Therapeutics Announces Tcelna™ as New Brand Name for MS Therapy
Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis.

Pages